| Trial ID: | L2913 |
| Source ID: | NCT04624672
|
| Associated Drug: |
Semaglutide (1 Mg Dose)
|
| Title: |
Treatment of GLP-1 for Diabetic Bariatric Patients
|
| Acronym: |
NOVO-GLP1
|
| Status: |
TERMINATED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT04624672/results
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Semaglutide (1 Mg Dose)|DRUG: Placebo
|
| Outcome Measures: |
Primary: RATE OF PARTIAL REMISSION OF DIABETES, HbA1C \< 6.5%, fasting glucose \<125 mg/dl, or no medications or active treatment for one year, 11 months | Secondary: RATE OF COMPLETE REMISSION OF DIABETES, HbA1C \< 6.0%, fasting glucose \<100 mg/dl, or no medications or active treatment for o, 11 months
|
| Sponsor/Collaborators: |
Sponsor: Geisinger Clinic | Collaborators: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
3
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2021-08-25
|
| Completion Date: |
2022-08-17
|
| Results First Posted: |
2023-02-08
|
| Last Update Posted: |
2023-11-14
|
| Locations: |
Geisinger Medical Center, Danville, Pennsylvania, 17822, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT04624672
|
